Rigel Pharmaceuticals (RIGL) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[5], including 1 Phase 3[1], 2 Phase 2[2], 1 Phase 1[3], 1 Phase 4[4].
Trial NCT04138927[6] evaluates Fostamatinib disodium in Warm Antibody Autoimmune Hemolytic Anemia with a target enrollment of 90 participants.
No Form 4 insider filings for RIGL were recorded at the SEC in the past 30 days[7].